Leukemia

The Food and Drug Administration granted a priority review to Blincyto for the treatment of early-stage CD19-positive B-cell acute lymphoblastic leukemia.

The Food and Drug Administration is requesting that CAR-T cell therapies now come with a Boxed Warning about secondary malignancies that have been reported in patients who undergo these treatments.

Financial burdens from medical costs negatively affect quality of life in patients who have received stem cell transplants, recent research showed.

Newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia had better outcomes when receiving Scemblix, compared with a different TKI, a study found.

Patients with Down syndrome and B-cell acute lymphoblastic leukemia tended to have higher rates of treatment-related deaths and poorer overall survival than those without Down syndrome.

Among patients with relapsed chronic lymphocytic leukemia (CLL) who expressed frequent baseline BTK mutations, responses on the non-covalent BTK inhibitor Jaypirca remained high, according to data presented at the 2023 ASH Annual Meeting.

A comparison of Scemblix (asciminib) and Bosulif (bosutinib) demonstrated greater efficacy and safety/tolerability with asciminib for patients with chronic phase chronic myeloid leukemia.

Recently approved by the FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Jaypirca “represents a meaningful advance” in treatment, as one expert explained.

Children and adults with relapsed/refractory KMT2A rearranged acute leukemia may obtain promising response rates with revumenib, a novel targeted therapy.

A novel cell therapy demonstrated early efficacy and an acceptable safety profile in patients with graft-versus-host disease undergoing haploidentical stem cell transplantation.

The three-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid-refractory or dependent chronic graft-versus-host disease benefited more with Jakafi compared with the best available treatment.

Molecular minimal residual disease status may offer clues as to which patients with acute monocytic leukemia will benefit from certain therapies.

Treatment with an all-oral regimen led to three-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia, a subset of acute myeloid leukemia.

As Billy Bean, MLB VP, revealed a cancer diagnosis and Toronto Blue Jays sportscaster, Jamie Campbell showed pre-skin cancer photo, here is what’s happening in the oncology space this week.

From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.

An expert discusses the FDA’s investigation into the possible association between CAR-T cell therapy and secondary T-cell malignancies.

Following promising study results, a Biologics License Application has been filed with the FDA for obe-cel (obecabtagene autoleucel), a CAR-T cell therapy for patients with relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (ALL).

The FDA announced rare instances of secondary diseases or cancers from CAR-T cell therapy, though this is not the first time that oncology treatments have been associated with secondary diseases.

In honor of National Family Caregiver’s Month, CURE® highlights some of the most important news in 2023.

An expert provided an overview of the promising therapies that are being investigated for the treatment of patients with chronic lymphocytic leukemia.

One doctor tells CURE why the FDA’s approval of the TKI Bosulif to treat children with chronic myelogenous leukemia “is really important.”

The FDA approved Bosulif for children aged 1 and older with newly diagnosed or resistant/intolerant chronic myelogenous leukemia.

After a stem cell donor saved the life of a patient with a rare leukemia, the two finally had a “very emotional” meeting this past spring in New York.

Patients with acute myeloid leukemia who took vitamin C and D supplements experienced fewer complications, but no overall survival benefits.

Iclusig plust reduced-intensity bested Gleevec when it came to MRD-negative complete remission in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.